BARD1 and ovarian carcinoma: Several additional case-control studies confirmed that no evidence of association was observed between ovarian cancer risk and pathogenic variants in BARD1 (OR 0.59, 95% CI 0.21–1.68 [26]; SSR 1.28, 95% CI 0.55–2.51 [27]; OR 1.4, 95% CI 0.7–2.9 [29]).